KC 706
Alternative Names: KC706Latest Information Update: 08 Oct 2014
At a glance
- Originator Kemia
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Cardiovascular therapies; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipidaemia; Pemphigus vulgaris; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 08 Oct 2014 Discontinued - Phase-II for Hyperlipidaemia in Europe (PO)
- 08 Oct 2014 Discontinued - Phase-II for Pemphigus in USA (PO)
- 08 Oct 2014 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)